The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2022 | DS-7300 demonstrates durable antitumor activity in advanced solid tumors
Toshihiko Doi, MD, PhD, National Cancer Center Hospital East, Chiba, Japan, shares the results of an extended follow-up of a Phase I/II (NCT04145622) investigating DS-7300, a B7-H3–directed antibody-drug conjugate (ADC) with a topoisomerase I inhibitor payload (DXd), in various cancers including small cell lung cancer (SCLC), metastatic castration-resistant prostate cancer (mCRPC) and non-small cell lung cancer (NSCLC). DS-7300 continues to demonstrate evidence of durable antitumor activity in heavily pre-treated patients. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
